Показано 0 из 0
Дата |
---|
09:05 |
02.05.2024 |
18.03.2024 |
15.03.2024 |
14.03.2024 |
13.03.2024 |
12.03.2024 |
11.03.2024 |
08.03.2024 |
07.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
3.72
|
4.10
|
4.04
|
4.04
|
4.04
|
4.04
|
|
|
|
|
3.92
|
4.00
|
4.04
|
4.04
|
4.04
|
4.04
|
|
|
|
|
|
|
4.04
|
4.04
|
4.04
|
4.04
|
|
|
|
|
3.92
|
4.08
|
4.04
|
4.04
|
4.04
|
4.04
|
|
|
|
|
3.90
|
4.10
|
3.90
|
3.90
|
3.90
|
3.90
|
|
|
|
|
3.88
|
4.28
|
3.80
|
3.80
|
3.80
|
3.80
|
|
|
|
|
3.70
|
4.08
|
3.72
|
3.72
|
3.72
|
3.72
|
|
|
|
|
3.64
|
3.86
|
3.68
|
3.68
|
3.68
|
3.68
|
|
|
|
|
3.64
|
3.76
|
3.60
|
3.60
|
3.60
|
3.60
|
|
|
|
|
3.56
|
3.64
|
3.60
|
3.60
|
3.60
|
3.60
|
|
|
|
|
Marker Therapeutics, Inc., formerly known as TapImmune, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.